Objectives To study the release of cupric ions and indomethacin from copper-bearing intrauterine devices (Cu-IUDs) and to assess the influence of their surface area of copper and the pH of the test medium on the release of cupric ions. Methods Cu-IUDs were incubated in simulated uterine fluid (SUF). The in vitro release of cupric ions and indomethacin was determined by means of a flame atomic absorption spectrometer and a UV 752 spectrophotometer, respectively, over a period of 220 days. The effect of indomethacin on the pH of the SUF was monitored during the cupric ions release study. Results The Cu-IUDs released cupric ions in vitro according to a biphasic pattern. After an initial burst release, the rate slowed down and then became steady. The release of indomethacin from two medicated Cu-IUDs was biphasic and, in both cases, in accordance with the in vitro dissolution model of the drug. The surface area of copper of Cu-IUDs and the pH change induced by indomethacin incorporated in their frame affected the release rate of copper (p < 0.05). Conclusion The surface area of the copper and the pH of the test medium modulate the in vitro release of cupric ions from Cu-IUDs.
Leukemia-associated alternative splicing of IKZF1 can result in proteins with loss of one to four copies of its N-terminal zinc finger domains (N-ZnF). The best characterized pathogenic splice isoforms, Ik-6 and Ik-8, have been commonly found in BCR-ABL1+ acute lymphoblastic leukemia (ALL) and a subset of BCR-ABL1-like ALL. Infantile and childhood ALL that express these pathogenic IKZF1 isoforms have shown inferior clinical outcomes and can be resistant to tyrosine kinase inhibitors. Using ALL cell lines, we designed and validated a method to detect abnormal IKZF1 transcripts. In the SUP-B15 leukemia cell line, we noted novel IKZF1 transcripts that include both an Ik-6 splice and a transcript with a 14 base pair insertion at the C-terminus. There was also increased IKZF2 protein in SUP-B15 as compared to other ALL lines. Expression of Ik-6 could be suppressed by treatment with the pro-apoptotic type II histone deacetylase inhibitor givinostat. In 17 adult ALL samples, we noted the Ik-6 isoforms in 6 of 15 BCR-ABL1−, and 1 of 2 BCR-ABL1+ cases, with Ik-8 also expressed in one case. Cases with Ik-6 expression showed inferior survival as well as older age at presentation, lower expression of CD10 and more commonly a diploid karyotype.
About Me
Paediatrician/ neonatologist from The Third Xiangya Hospital of Central South University, China
Paediatrician/ neonatologist from The Third Xiangya Hospital of Central South University, China